Phreesia/$PHR
1D1W1MYTD1Y5YMAX
Capital at risk
About Phreesia
Phreesia Inc is a provides an integrated software, payments, and engagement platform designed to address three foundational challenges in healthcare delivery: access to care, affordability of care, and patient health outcomes. Its platform is embedded directly into provider workflows and patient interactions, enabling healthcare organizations to activate patients, streamline administrative processes, and improve financial performance across the care continuum. The group serves a diverse group of healthcare organizations, including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest, and not-for-profit and other organizations.
- Ticker
- $PHR
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,789
- Headquarters
- Wilmington, United States
- Website
- www.phreesia.com
Phreesia Metrics
BasicAdvanced
$623M
58.45
$0.17
0.86
-
Price and volume
Market cap
$623M
Beta
0.86
52-week high
$25.00
52-week low
$7.77
Average daily volume
789K
Financial strength
Current ratio
1.762
Quick ratio
1.441
Long term debt to equity
0.166
Total debt to equity
0.183
Interest coverage (TTM)
2.14%
Profitability
EBITDA (TTM)
49.137
Gross margin (TTM)
67.57%
Net profit margin (TTM)
2.06%
Operating margin (TTM)
5.01%
Effective tax rate (TTM)
-277.97%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
3.01%
Return on equity (TTM)
3.12%
Valuation
Price to earnings (TTM)
58.448
Price to revenue (TTM)
1.202
Price to book
1.68
Price to tangible book (TTM)
8.68
Price to free cash flow (TTM)
9.043
Free cash flow yield (TTM)
11.06%
Free cash flow per share (TTM)
1.11
Growth
Revenue change (TTM)
12.93%
Earnings per share change (TTM)
-141.30%
3-year revenue growth (CAGR)
16.72%
3-year earnings per share growth (CAGR)
-60.88%
What the Analysts think about Phreesia
Analyst ratings (Buy, Hold, Sell) for Phreesia stock.
Analyst projections of the future price of Phreesia stock.
Bulls say / Bears say
Phreesia launched ProviderConnect on March 3, 2026, an AI‐driven clinician marketing solution designed to engage providers using real‐world care signals and pre-appointment data, expanding its product suite (Reuters)
The November 12, 2025 acquisition of AccessOne is projected to add approximately $8 million of annualized revenue and $11 million of Adjusted EBITDA, significantly bolstering Phreesia’s payment solutions segment (S&P Global)
In Q2 FY2027 (ended July 31, 2026), Phreesia generated net income of $1.9 million and free cash flow of $13.8 million, reflecting strong operational execution and continued profitability expansion (SEC filing)
Adjusted EPS of $0.03 in Q2 FY2027 fell short of the $0.09 analyst consensus, driving a 10% share price decline as investors reacted negatively to the bottom‐line miss (Investing.com)
Phreesia noted increased variability in its internal network solutions revenue forecasting for the second half of fiscal 2027, suggesting less predictability in one of its higher‐growth segments (SEC filing)
The company is carrying significant leverage following a $110 million bridge loan used to fund the AccessOne acquisition and a new $275 million revolving credit facility, increasing interest expense and refinancing risk (SEC filing)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
Phreesia Financial Performance
Revenues and expenses
Phreesia Earnings Performance
Company profitability
Upcoming events
No upcoming events
Phreesia News
AllArticlesVideos
Funds containing Phreesia
AllEURUSDGBP
Fund name | Fund size | $PHR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Vanguard ESG Global All Cap£V3AB | £905M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.